The global adiponectin testing market size was valued at USD 37.30 billion in 2025 and is projected to grow from USD 40.41 billion in 2026 to USD 76.77 billion by 2034, registering a CAGR of 8.35% during the forecast period (2026-2034). North America dominated the adiponectin testing market with a share of 41.73% in 2025.
Adiponectin testing is a laboratory procedure used to measure adiponectin hormone levels in blood serum or plasma. The test supports research on insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. Adiponectin testing reagents are classified under HSN Code 38221990 (other diagnostic or laboratory reagents), while clinical testing laboratories fall under SIC Code 8071 (medical laboratories).
The adiponectin testing market demand is driven by increasing research on metabolic disorders, growing interest in adiponectin as a biomarker of insulin sensitivity, and the use of hormone-based diagnostic assays. The development of high-sensitivity assay kits and expanding biomarker validation studies contribute to adiponectin testing market growth.
Download a Free Sample To learn more about this report,
Preference for High-Molecular-Weight Adiponectin Testing
The adiponectin testing market analysis indicates interest in high-molecular-weight (HMW) adiponectin measurement for metabolic research. HMW adiponectin is closely associated with insulin sensitivity, supporting its assessment in obesity and diabetes studies. For example, R&D Systems offers a Human HMW Adiponectin Quantikine ELISA Kit with a sensitivity of 0.989 ng/mL, supporting specific measurement of this adiponectin form in serum and plasma samples.
Adoption of High-Sensitivity Adiponectin Assays
High-sensitivity adiponectin assays are gaining importance in research applications requiring accurate hormone measurement at low concentrations. Laboratory researchers are focusing on assay sensitivity, sample compatibility, and reproducibility to improve testing reliability. This trend supports demand for validated ELISA kits capable of measuring adiponectin in serum and plasma.
Supply chain disruptions are expected to have a moderate impact on the adiponectin testing market share due to shortages of assay antibodies, ELISA reagents, microplates, and laboratory consumables. The market is expected to experience a K-shaped recovery as established manufacturers with diversified suppliers can maintain production. Smaller assay kit manufacturers remain more exposed to reagent shortages and higher procurement costs. The market is projected to grow at a CAGR of 8.35%. An assumed 1 percentage point reduction from supply constraints could lower short-term growth to 7.35%. Improved reagent availability and stable distribution networks are expected to support recovery toward 8.35%.
The adiponectin testing market forecasts investment activity supported by acquisitions of life science assay manufacturers and expansion of laboratory manufacturing capabilities.
Key Investment and Funding Activities in Adiponectin Testing Market, 2025
Focus on Obesity-Related Metabolic Dysfunction and Increasing Diabetes Prevalence Drives Market
Focus on obesity-related metabolic dysfunction is strengthening demand for adiponectin testing in research laboratories. Adiponectin levels are associated with insulin sensitivity and fat tissue function, making the hormone an important biomarker in obesity research. Research institutions are increasingly studying these associations to better understand metabolic abnormalities, supporting demand for adiponectin testing in obesity-related investigations.
High prevalence of diabetes is strengthening demand for adiponectin testing in metabolic research. Adiponectin supports investigations into insulin resistance and diabetes-related metabolic dysfunction. According to the International Diabetes Federation's 2025 Diabetes Atlas, approximately 589 million adults had diabetes in 2024, with the number projected to reach 853 million by 2050, representing nearly 45% growth. This increasing disease burden supports continued research into adiponectin as a metabolic biomarker.
Lack of Standardized Reference Ranges Limits and Complex Sample Preparation & Storage Requirements Restrain Market Expansion
Absence of universally accepted adiponectin reference ranges is restricting its adoption in routine clinical testing. Different assay methods can produce varying results, making comparisons between laboratories difficult. Adiponectin concentrations also require careful interpretation because levels vary across metabolic conditions. These limitations reduce confidence in using adiponectin as an independent diagnostic marker.
Adiponectin testing requires precise sample preparation to ensure reliable laboratory results. High sample dilution requirements increase handling time and the risk of measurement errors. For example, Abcam's Human Adiponectin ELISA Kit (ab99968) recommends a 30,000-fold dilution for normal serum and plasma samples. Such extensive dilution procedures require careful pipetting and trained laboratory personnel.
Development of Electrochemical Biosensors and Integration of Multiplex Mass Spectrometry Creates Opportunities for Market Growth
Advancements in electrochemical biosensors are creating opportunities for faster adiponectin measurement outside conventional laboratory settings. These technologies offer high analytical sensitivity and require smaller sample volumes compared with conventional testing methods. Further development of automated biosensor platforms could support rapid adiponectin measurement and expand testing applications in metabolic health monitoring and decentralized diagnostic facilities.
Development of multiplex mass spectrometry assays is creating opportunities for simultaneous measurement of adiponectin and other metabolic biomarkers. This technology enables laboratories to assess multiple adipokines, including leptin and resistin, from a single plasma sample. The combined analysis of these biomarkers can improve laboratory efficiency and provide a broader understanding of metabolic dysfunction.
Assay kits dominated the product segment with a share of 49.50% in 2025, owing to growing demand for standardized adiponectin measurements in metabolic research laboratories. Premeasured reagents and established calibration procedures encourage repeat purchasing for ongoing metabolic research programs.
Software & analysis solutions will expand to 9.95% CAGR during the forecast period, due to increasing requirements for assay curve fitting and quality control. Automated result interpretation helps laboratories identify measurement variation and manage datasets.
Request Customizationto receive a tailored report.
In 2025, ELISA had a share of 44.80%, supported by widespread laboratory avilability and growing use of quantitative adiponectin assays in metabolic research. Compatible microplate readers and established assay protocols support routine testing without requiring additional specialized laboratory instrumentation.
Multiplex immunoassay is estimated to register a growth rate of 9.85% during the forecast period, supported by growing interest in measuring adiponectin alongside other related adipokines. Simultaneous protein analysis reduces sample consumption and increases testing efficiency in studies requiring comprehensive metabolic biomarker profiles and comparisons.
Diabetes & metabolic syndrome research led the application segment with a share of 36.50% in 2025. This dominance is attributed to rising investigation of insulin resistance and adiponectin regulation. Researchers increasingly measure circulating adiponectin to examine relationships between metabolic dysfunction and impaired glucose control.
Biomarker discovery & clinical research is projected to undergo growth at a CAGR of 16.30% during the forecast period, driven by increasing investigation of adiponectin isoforms for metabolic risk assessment. Greater emphasis on biomarker validation encourages systematic comparisons across patient groups and disease stages.
Research & academic institutes dominated the end user industry in 2025, accounting for a share of 35.60%. This growth is supported by increasing government-funded metabolic research projects. University research laboratories require adiponectin assays for longitudinal studies and experimental investigations into adipose tissue function.
Pharmaceutical & biotechnology companies is likely to witness a CAGR of 9.15% during the forecast period. This growth is attributed to increasing investments in metabolic drug development programs. Adiponectin testing supports preclinical compound screening and pharmacodynamic assessments, strengthening demand across drug development laboratories.
Speak to an Analystto discuss market opportunities.
The North America adiponectin testing market accounted for the largest regional share of 41.73% in 2025.
National Institute of Diabetes and Digestive and Kidney Diseases supports research into insulin resistance and adipose tissue function. The country's established biomedical laboratory network facilitates adiponectin measurement using ELISA and other immunoassay methods. Federal research funding and the presence of specialized metabolic research facilities strengthen demand for adiponectin testing in diabetes research and biomarker evaluation.
Canadian Institutes of Health Research supports investigations into obesity and metabolic disorders through its Institute of Nutrition, Metabolism and Diabetes. University-affiliated research hospitals conduct adipose tissue research to understand insulin resistance and related metabolic abnormalities. The country's publicly funded biomedical research system supports demand for adiponectin assay kits across academic laboratories and specialized research facilities.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific adiponectin testing market is expected to grow at a CAGR of 10.06% during the forecast period, showcasing the fastest-growing regional market.
China's National Natural Science Foundation supports biomedical investigations into diabetes and metabolic disease mechanisms. The country's domestic manufacturing capabilities improve the availability of laboratory reagents and immunoassay products. Government investment in research infrastructure also strengthens laboratory testing capacity. These factors support demand for adiponectin ELISA kits and related testing technologies across university laboratories and metabolic disease research institutions.
National Programme for Prevention and Control of Non-Communicable Diseases supports diabetes screening among adults aged 30 years and above. The Ministry of Health and Family Welfare reports the establishment of 770 district-level NCD clinics and 6,410 community health centre clinics. This extensive screening infrastructure increases attention to metabolic risk assessment. The growing need for advanced metabolic biomarkers creates opportunities for adiponectin testing in specialized diagnostic and research facilities.
University of Tokyo's Department of Diabetes and Metabolic Diseases conducts specialized research on adiponectin receptors AdipoR1 and AdipoR2, which regulate insulin sensitivity and metabolic functions. Japan's biomedical research institutions also investigate adiponectin signaling as a potential therapeutic target for type 2 diabetes. These activities support demand for adiponectin measurement in receptor-related research and metabolic drug development, strengthening the country's specialized testing market.
Europe's adiponectin testing market is expected to grow at a CAGR of 7.95% during the forecast period.
NHS Health Check program provides diabetes and cardiovascular risk assessments for eligible adults aged 40 to 74. The National Institute for Health and Care Research supports investigations into metabolic diseases and potential biomarkers. Adiponectin testing remains primarily a research application rather than a routine NHS screening procedure. The country's clinical research infrastructure supports demand for adiponectin assays in metabolic biomarker investigations.
German Center for Diabetes Research coordinates metabolic disease investigations across specialized research institutions. Its research activities focus on diabetes development and biological mechanisms associated with insulin resistance. Germany's established laboratory infrastructure supports quantitative adiponectin measurement and adipokine analysis. The presence of specialized diabetes research centers strengthens demand for immunoassay-based adiponectin testing across academic and biomedical research laboratories.
The Latin America adiponectin testing market is expected to grow at a CAGR of 8.75% during the forecast period. Brazil's Ministry of Health operates the Vigitel surveillance system, which monitors diabetes and obesity risk factors across 26 state capitals and the Federal District. This supports interest in adiponectin-based metabolic risk research. Mexico's National Institute of Public Health conducts nationwide health and nutrition assessments across 32 states, strengthening the evidence base for research into insulin resistance and related biomarkers. These factors support adiponectin testing demand in specialized laboratories.
The Middle East & Africa adiponectin testing market is expected to grow at a CAGR of 8.95% during the forecast period. Abu Dhabi's Department of Health recognizes specialized diabetes research centers, including the Imperial College London Diabetes Centre, within its authorized research network. South Africa's Medical Research Council operates the Biomedical Research and Innovation Platform, which investigates obesity-related metabolic mechanisms and disease biomarkers. These initiatives support demand for adiponectin testing in specialized research laboratories.
The adiponectin testing market competitive landscape is moderately fragmented, with competition comprising global life science companies, specialized immunoassay manufacturers, and regional diagnostic reagent suppliers. Key players such as Fisher, Bio-Techne, Merck , Abcam, Bio-Rad, and Crystal Chem are estimated to account for 30% of the global adiponectin testing market share.
Established players compete primarily on assay sensitivity, measurement accuracy, and distribution capabilities. Emerging and regional players in the adiponectin testing market ecosystem compete through specialized adiponectin isoform assays and customized biomarker solutions.
June 2026: Merck KGaA signed a definitive agreement to acquire Bio-Techne for approximately USD 11.3 billion, expanding its life science reagent and analytical technology portfolio.
December 2025: Bio-Techne launched its enhanced Leo System with multiplex protein analysis capabilities, enabling simultaneous detection of up to 24 targets per sample.
July 2025: Bio-Techne partnered with Spear Bio to distribute ultrasensitive immunoassays for low-abundance protein biomarkers,
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Antigen Skin Test Market Size, Forecast, Demand, Opportunities, 2034
Ultrasound Devices Market Size, Share, Growth, Analysis, 2034
Electrophysiology Market Size, Forecast, Opportunities, 2034
Blood Glucose Monitoring Devices Market Size, Forecast, Demand, Opportunities, 2034
Autoclaves Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com